BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Innovation in Global Public Health - Discovery of Bedaquiline for 
 TB and Impact of AI for drug discovery
DTSTART:20260729T103000Z
DTEND:20260729T123000Z
DTSTAMP:20260803T143700Z
UID:indico-event-9382@scitalks.tifr.res.in
DESCRIPTION:Speakers: Anil Koul (Mankind Pharma / BSV  (London School of H
 ygiene  & Tropical Medicine\, UK))\n\nBedaquiline is the first new drug di
 scovered for the treatment of drug-resistant tuberculosis (TB) after a gap
  of 45 years. This talk will cover its discovery\, the challenges of its d
 evelopment\, and its transformative impact on the lives of TB patients. It
  will also highlight the latest anti-TB drugs in the clinical development 
 pipeline that could help India and the world move towards TB elimination. 
 Finally\, the session will explore how artificial intelligence (AI) can ac
 celerate drug discovery for neglected diseases such as TB\, reduce the mul
 ti-billion-dollar costs of pharmaceutical R&D\, and democratize innovation
  and access to new medicines for underserved populations.\n\nhttps://scita
 lks.tifr.res.in/event/9382/
LOCATION:AG66
URL:https://scitalks.tifr.res.in/event/9382/
END:VEVENT
END:VCALENDAR